Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings

Question of the Month

What does the future hold for CRISPR base editing of PCSK9?
Professor Kiran Musunuru

Prof Kiran Musunuru (Professor and Genetics Researcher at University of Pennsylvania, USA) discusses the prospects.

Find out more »

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »
Most viewed

Hot Topics

15th Virtual Closed Scientific Expert Meeting of the Editorial Board
Critical questions in PCSK9 research
Dhruv KaziWhere next for cost-effectiveness analysis of combination LDL lowering therapies?

Dr Dhruv Kazi focuses on future considerations for these analyses.

Watch now

Kiran MusunuruIs a 'once-and-done' approach to LDL lowering feasible?

Prof Kiran Musunuru overviews latest developments with CRISPR base editing of PCSK9.

Watch now

From the Editors

Proof-of-concept: Gene-editing for PCSK9 inhibition

Prof. John Chapman, Pitié-Salpêtrière University Hospital, Sorbonne University, and National Institute for Health and Medical Research (INSERM), Paris, France.

Read the report

 

Other related reports:

DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe

Pooled analysis highlights the promise of inclisiran

Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial

Very low lipoprotein(a) and very low LDL cholesterol – are they safe?

Latest Event

AHA 2021 Scientific sessions 13th-15th November

AHA 2021 Scientific Sessions
13th-15th November

View all reports »

Upcoming Events

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology